Terpstra Matty L, Singh Ramandeep, Geerlings Suzanne E, Bemelman Frederike J
Matty L Terpstra, Ramandeep Singh, Suzanne E Geerlings, Frederike J Bemelman, Division of Nephrology, Division of Infectious Diseases, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, 1100 DD Amsterdam, The Netherlands.
World J Nephrol. 2016 Jul 6;5(4):378-88. doi: 10.5527/wjn.v5.i4.378.
To evaluate methods measuring the intestinal per-meability in chronic kidney disease (CKD) and clarify whether there is an increased intestinal permeability in CKD.
We reviewed the literature in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) protocol and performed a systematic literature search through MEDline and EMBASE. All controlled trials and cohort studies using non-invasive methods to assess intestinal permeability in CKD patients were included. Excluded were: Conference abstracts and studies including patients younger than 18 years or animals. From the included studies we summarized the used methods and their advantages and disadvantages. For the comparison of their results we divided the included studies in two categories based on their included patient population, either assessing the intestinal permeability in mild to moderate CKD patients or in end stage renal disease (ESRD) patients. Results were graphically displayed in two plots, one comparing the intestinal permeability in mild to moderate CKD patients to healthy controls and one comparing the intestinal permeability in ESRD patients to healthy controls.
From the 480 identified reports, 15 met our inclusion criteria. Methods that were used to assess the intestinal permeability varied from markers measured in plasma to methods based on calculating the urinary excretion of an orally administered test substance. None of the applied methods has been validated in CKD patients and the influence of decreased renal function on the different methods remains unclear to a certain extent. Methods that seem the least likely to be influenced by decreased renal function are the quantitative PCR (qPCR) for bacterial DNA in blood and D-lactate. Considering the results published by the included studies; the studies including patients with mild to moderate CKD conducted conflicting results. Some studies did report an increase in intestinal permeability whilst other did not find a significant increased permeability. However, despite the variety in used methods among the different studies, all studies measuring the intestinal permeability in ESRD point out a significant increased intestinal permeability. Results should nevertheless be interpreted with caution due to the possible influence of a decreased glomerular filtration rate on test results.
The intestinal permeability in CKD: (1) could be measured by qPCR for bacterial DNA in blood and D-lactate; and (2) seems to be increased in ESRD.
评估慢性肾脏病(CKD)患者肠道通透性的测量方法,并阐明CKD患者的肠道通透性是否增加。
我们按照系统评价和Meta分析的首选报告项目(PRISMA)方案对文献进行综述,并通过MEDline和EMBASE进行系统的文献检索。纳入所有使用非侵入性方法评估CKD患者肠道通透性的对照试验和队列研究。排除标准为:会议摘要以及纳入18岁以下患者或动物的研究。从纳入的研究中,我们总结了所使用的方法及其优缺点。为了比较研究结果,我们根据纳入的患者群体将纳入的研究分为两类,即评估轻度至中度CKD患者或终末期肾病(ESRD)患者的肠道通透性。结果以两个图表的形式直观呈现,一个比较轻度至中度CKD患者与健康对照的肠道通透性,另一个比较ESRD患者与健康对照的肠道通透性。
在480篇已识别的报告中,15篇符合我们的纳入标准。用于评估肠道通透性的方法各不相同,从血浆中测量的标志物到基于计算口服测试物质的尿排泄量的方法。所应用的方法均未在CKD患者中得到验证,并且肾功能下降对不同方法的影响在一定程度上仍不明确。受肾功能下降影响最小的方法似乎是血液中细菌DNA的定量聚合酶链反应(qPCR)和D-乳酸。考虑到纳入研究发表的结果;纳入轻度至中度CKD患者的研究结果相互矛盾。一些研究确实报告肠道通透性增加,而其他研究未发现通透性有显著增加。然而,尽管不同研究中使用的方法各异,但所有测量ESRD患者肠道通透性的研究均指出肠道通透性显著增加。不过,由于肾小球滤过率下降可能对测试结果产生影响,结果仍应谨慎解释。
CKD患者的肠道通透性:(1)可通过血液中细菌DNA的qPCR和D-乳酸进行测量;(2)在ESRD患者中似乎增加。